Silverberg Bernstein Capital Management LLC Invests $1.46 Million in Johnson & Johnson (NYSE:JNJ)

Silverberg Bernstein Capital Management LLC bought a new position in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 9,300 shares of the company’s stock, valued at approximately $1,458,000. Johnson & Johnson accounts for 1.4% of Silverberg Bernstein Capital Management LLC’s holdings, making the stock its 18th largest holding.

Other institutional investors and hedge funds also recently modified their holdings of the company. State Street Corp boosted its holdings in Johnson & Johnson by 1.1% in the second quarter. State Street Corp now owns 141,833,756 shares of the company’s stock valued at $23,476,323,000 after purchasing an additional 1,568,633 shares during the last quarter. Moneta Group Investment Advisors LLC boosted its holdings in Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Morgan Stanley boosted its holdings in Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Norges Bank purchased a new position in Johnson & Johnson in the fourth quarter valued at about $4,609,399,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Johnson & Johnson by 1.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on JNJ shares. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Raymond James increased their target price on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $180.00 in a report on Friday, December 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Johnson & Johnson Stock Up 1.4 %

Shares of Johnson & Johnson stock opened at $157.96 on Thursday. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $380.65 billion, a price-to-earnings ratio of 11.44, a PEG ratio of 2.62 and a beta of 0.53. The business’s 50 day simple moving average is $158.76 and its 200-day simple moving average is $156.69.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. During the same period last year, the firm earned $2.35 EPS. The firm’s revenue was down 9.7% compared to the same quarter last year. Equities research analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were given a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 3.01%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.